{
  "nctrialId": "HC-1389",
  "title": "A Randomized Open-Label, Placebo-Controlled  Study of AST-611 (anti-IL-5 antibody) in Patients With Psoriasis",
  "officialTitle": "A Randomized Open-Label, Placebo-Controlled  Study of AST-611 (anti-IL-5 antibody) in Patients With Psoriasis",
  "sponsor": "Dalhousie University",
  "indication": "Psoriasis",
  "phase": "Phase 2/Phase 3",
  "fileName": "HC-1389.json",
  "fileSize": 589592,
  "date": "2023-07-27",
  "completionDate": "2027-06-02",
  "drugName": "AST-611 (anti-IL-5 antibody)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Recruiting",
  "description": "This is a randomized open-label, placebo-controlled  study designed to evaluate the efficacy and safety of AST-611 (anti-IL-5 antibody) in patients with Psoriasis. The study will enroll approximately 382 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 23-73 years\n- Confirmed diagnosis of Psoriasis\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment",
  "csr_id": "HC-1389"
}